



Publication in accordance with Section 111c (4) AktG - Publication of significant transactions with related parties

Carl Zeiss Meditec AG enters into a new trademark license agreement with Carl Zeiss AG

Jena, 10 September 2021

On 10 September 2021, Carl Zeiss Meditec AG, Jena (ISIN: DE0005313704), entered into a new trademark license agreement for the commercial continued use of the ZEISS brand with Carl Zeiss AG, Oberkochen, Germany, as the licensor. Carl Zeiss AG directly and indirectly holds a total stake of around 59% in Carl Zeiss Meditec AG.

Under this agreement, Carl Zeiss Meditec AG will pay Carl Zeiss AG annual trademark license fees in equivalent to 1.5% of the average revenue of the last five fiscal years preceding the year of the agreement. An initial expense of around €20m is expected for the coming fiscal year 2021/22. The term of the trademark license agreement is three years, starting on 1 October 2021, and will be automatically extended by a further two years unless either party objects to it with a six weeks' notice at the end of the term. Total trademark license expenses of more than €60m are expected over the three-year period. The agreement replaces an earlier trademark licensing agreement between Carl Zeiss Meditec AG and the ZEISS Group which had the same material terms and conditions. The formula for calculating the trademark license expense remains unchanged compared to the previous agreement. Therefore, the new trademark licensing agreement has no impact on the Company's financial targets.

In the opinion of the Management Board of Carl Zeiss Meditec AG, the terms and conditions of the trademark license agreement continue to be considered as customary in the market, as was the case in the previously concluded trademark license agreement. The Management Board regularly reviews market conformity, taking into account the resources invested by Carl Zeiss AG in the brand image and the services provided to Carl Zeiss Meditec AG.



Contact for investors and press

Sebastian Frericks

Head of Investor Relations

Carl Zeiss Meditec AG

Phone: +49 3641 220-116

Email: investors.meditec@zeiss.com

Brief profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the TecDAX and MDax of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,290 employees worldwide, the Group generated revenue of €1,335.5m in fiscal year 2019/20 (to 30 September).

The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain, France and Turkey. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.de/med